Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
SCPH scPharmaceuticals
- 2.550
- -0.050-1.92%
Trading Apr 24 10:12 ET
128.22MMarket Cap-1.34P/E (TTM)
2.590High2.550Low18.55KVolume2.590Open2.600Pre Close47.53KTurnover0.07%Turnover RatioLossP/E (Static)50.28MShares5.65052wk High9.62P/B68.58MFloat Cap1.94052wk Low--Dividend TTM26.89MShs Float18.170Historical High--Div YieldTTM1.54%Amplitude1.940Historical Low2.562Avg Price1Lot Size
scPharmaceuticals Stock Forum
Sign in to post a comment
$scPharmaceuticals (SCPH.US)$ scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Cash and cash equivalents of $75.7 million as of December 31, 2024
U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overloa...
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Cash and cash equivalents of $75.7 million as of December 31, 2024
U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overloa...
2
2
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
48
28
4
$scPharmaceuticals (SCPH.US)$ Reuters·
ScPharmaceuticals Inc: Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025
ScPharmaceuticals Inc: Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025
4
14
$scPharmaceuticals (SCPH.US)$ Reuters
·1 min ago
ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease
·1 min ago
ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease
2
$scPharmaceuticals (SCPH.US)$
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
Thursday, 6th March at 4:01 pm
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome
FUROSCIX is expected to be available ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
Thursday, 6th March at 4:01 pm
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome
FUROSCIX is expected to be available ...
2
$scPharmaceuticals (SCPH.US)$ upcoming pending FDA deiciion on 6th of March
1
$scPharmaceuticals (SCPH.US)$ Reuters· 2 mins ago
ScPharmaceuticals Inc - Observes Variability in Scp-111 Product Testing
Snda Submission for Scp-111 May Be Delayed
ScPharmaceuticals Inc - Observes Variability in Scp-111 Product Testing
Snda Submission for Scp-111 May Be Delayed
🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
8
No comment yet
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Trytosaveabit OP : Second bullet points is crazy increase! Hehehe
LeadByAnimals : Good numbers!! They beat the estimate so hopefully some positive market sentiment comes in the near future!! I would be very happy if the analysts were proven right on their projections for this one!! lol